Literature DB >> 10734285

Minimum risk weights for comparing treatments in stratified binomial trials.

D V Mehrotra1, R Railkar.   

Abstract

When comparing two treatments in a stratified trial with a binary endpoint, data are commonly analysed using a weighted averaging of the stratum-specific differences between proportions. Two popular sets of weights are the harmonic means of the stratum-specific sample sizes (SSIZE) and the reciprocals of the variances of the stratum-specific differences (INVAR). Either the SSIZE or INVAR weights are chosen and prespecified in the data analysis plan. We show that the 'wrong' choice between SSIZE and INVAR can result in a significantly inefficient analysis. To circumvent this potential problem, we propose a 'minimum risk' (MR) weighting strategy. The easy-to-compute MR weights are designed to yield more precise and less biased estimates of the overall treatment difference relative to the SSIZE and INVAR weights, respectively. We show, via a simulation study, that the proposed weights are an attractive compromise between the SSIZE and INVAR weights in terms of statistical power. Numerical examples are presented to illustrate the utility of the MR weights. Copyright 2000 John Wiley & Sons, Ltd.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10734285     DOI: 10.1002/(sici)1097-0258(20000330)19:6<811::aid-sim390>3.0.co;2-z

Source DB:  PubMed          Journal:  Stat Med        ISSN: 0277-6715            Impact factor:   2.373


  4 in total

1.  Conversion from Calcineurin Inhibitor to Belatacept-based Maintenance Immunosuppression in Renal Transplant Recipients: a Randomized Phase 3b Trial.

Authors:  Klemens Budde; Rohini Prashar; Hermann Haller; María Rial; Nassim Kamar; Avinash Agarwal; Johan de Fijter; Lionel Rostaing; Stefan Berger; Arjang Djamali; Nicolae Leca; Lisa Allamassey; Sheng Gao; Martin Polinsky; Flavio Vincenti
Journal:  J Am Soc Nephrol       Date:  2021-10-27       Impact factor: 10.121

2.  Safety, efficacy, and immunogenicity of VGX-3100, a therapeutic synthetic DNA vaccine targeting human papillomavirus 16 and 18 E6 and E7 proteins for cervical intraepithelial neoplasia 2/3: a randomised, double-blind, placebo-controlled phase 2b trial.

Authors:  Cornelia L Trimble; Matthew P Morrow; Kimberly A Kraynyak; Xuefei Shen; Michael Dallas; Jian Yan; Lance Edwards; R Lamar Parker; Lynette Denny; Mary Giffear; Ami Shah Brown; Kathleen Marcozzi-Pierce; Divya Shah; Anna M Slager; Albert J Sylvester; Amir Khan; Kate E Broderick; Robert J Juba; Timothy A Herring; Jean Boyer; Jessica Lee; Niranjan Y Sardesai; David B Weiner; Mark L Bagarazzi
Journal:  Lancet       Date:  2015-09-17       Impact factor: 79.321

3.  A small n sequential multiple assignment randomized trial design for use in rare disease research.

Authors:  Roy N Tamura; Jeffrey P Krischer; Christian Pagnoux; Robert Micheletti; Peter C Grayson; Yeh-Fong Chen; Peter A Merkel
Journal:  Contemp Clin Trials       Date:  2015-11-14       Impact factor: 2.226

4.  Ceftolozane/Tazobactam Plus Metronidazole for Complicated Intra-abdominal Infections in an Era of Multidrug Resistance: Results From a Randomized, Double-Blind, Phase 3 Trial (ASPECT-cIAI).

Authors:  Joseph Solomkin; Ellie Hershberger; Benjamin Miller; Myra Popejoy; Ian Friedland; Judith Steenbergen; Minjung Yoon; Sylva Collins; Guojun Yuan; Philip S Barie; Christian Eckmann
Journal:  Clin Infect Dis       Date:  2015-02-10       Impact factor: 9.079

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.